Presentations

    A novel method for multi-component continuous real-time aerosol monitoring using Fourier Transformed Infrared (FTIR) spectroscopy for in vivo studies

    Tan, W. T.; Krishnan , S.; Vanscheeuwijck, P.

    Conference date
    Sep 7, 2018
    Conference name

    International Aerosol Conference (IAC) 2018
    Link to more information
    Topic
    Summary

    No abstract available.

    Related Publications

    Fourier Transformed Infrared (FTIR) Method For Continuous Real-Time Aerosol Characterization For In Vivo Studies

    Aerosol Chemistry Pre-clinical Toxicology

    Reduced exposure evaluation of an Electrically Heated Cigarette Smoking System. Part 2: Smoke chemistry and in vitro toxicological evaluation using smoking regimens reflecting human puffing behavior

    Aerosol Chemistry Pre-clinical Toxicology

    Evaluation of the potential effects of ingredients added to cigarettes. Part 1: Cigarette design, testing approach, and review of results

    Aerosol Chemistry Pre-clinical Toxicology

    Mainstream smoke chemistry and in vitro and in vivo toxicity of the reference cigarettes 3R4F and 2R4F

    Aerosol Chemistry Pre-clinical Toxicology

    Progression of atherosclerosis in the Apo E−/− model: 12-Month exposure to cigarette mainstream smoke combined with high-cholesterol/fat diet

    Aerosol Chemistry Pre-clinical Toxicology

    The addition of cocoa, glycerol, and saccharose to the tobacco of cigarettes: Implications for smoke chemistry, in vitro cytotoxicity, mutagenicity and further endpoints

    Aerosol Chemistry Pre-clinical Toxicology

    PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
    ​
    Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.